Microvillus Inclusion Disease (MVID) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 

Microvillus inclusion disease (MVID) is a rare inherited and invariably deadly enteropathy characterized by severe, intractable secretory diarrhea and nutrient malabsorption. This diarrhea becomes so abundant that within 24H, the children can lose up to 30% of their body weight, resulting in profound metabolic acidosis and severe dehydration. MVID is diagnosed by evaluating symptoms, excluding more common causes of diarrhea, and evaluating intestinal biopsies. Intestinal biopsies of patients with MVID show villus hypoplasia in the small intestine but no signs of infection or inflammation. MVID is caused by loss of function changes (mutations) in the myosin Vb (Myo5b) gene, a molecular motor gene responsible for the traffic of proteins into the brush border of epithelial cells. Mutations cause most cases of MVID in Myo5b. However, mutations in syntaxin 3, a gene for a SNARE protein responsible for vesicle fusion with the membrane, have been reported in some patients with MVID with late presentation and milder disease.

  • Around 350 cases of Microvillus inclusion disease (MVID) are diagnosed yearly in the USA.

 

Thelansis’s “Microvillus Inclusion Disease (MVID) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Microvillus Inclusion Disease (MVID) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Microvillus Inclusion Disease (MVID) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Microvillus Inclusion Disease (MVID) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Microvillus Inclusion Disease (MVID) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033